Quick search:
| Result | Content | Outlet | Published | Research |
|---|---|---|---|---|
| Result | Content | Outlet | Published | Research |
| 1 | Chari Discusses Prominent Trials For Newly Diagnosed Multiple Myeloma | Targeted Oncology | 6 months ago | |
| 2 | Subcutaneous Daratumumab Plus Kd Is a “Gamechanger” for Patients With Multiple Myeloma | OncLive | 4 months ago | |
| 3 | Talquetamab/Daratumumab Shows Promise in Heavily Pretreated Myeloma, Warranting Further Investigation | OncLive | 3 months ago | |
| 4 | New Blood Tests Reduce Need for Bone Marrow Biopsy in Multiple Myeloma | Targeted Oncology | 2 months ago | |
| 5 | Mount Sinai Announces Landmark Gift from James S. and Merryl H. Tisch to Transform Cancer Care in New York | Mount Sinai | 9 months ago | |
| 6 | Experts discuss management of cancer therapies in the era of COVID-19 | Healio | 6 months ago | |
| 7 | Darzalex Faspro Combo Therapy for Myeloma Patients Approved by FDA | Myeloma Research News | 5 months ago | |
| 8 | TRIMM-2: favourable results of talquetamab plus daratumumab for multiple myeloma | Physician's Weekly | 5 months ago | |
| 9 | FDA Approves Time-Saving Combo for R/r Multiple Myeloma | Medscape | 6 months ago | |
| 10 | Priorities for Relapsed Multiple Myeloma Treatments | PPA | Dove Medical Press | 3 months ago | |
| 11 | ASH 2020 Data: DKd Versus DVd Implications | AJMC.com Managed Markets Network | 1 year ago | |
| 12 | Combination Regimens Show Different Levels of Efficacy for Patients With Myeloma Ineligible for Transplant | Targeted Oncology | 1 year ago | |
| 13 | Implications of the IKEMA Interim Analysis | AJMC.com Managed Markets Network | 1 year ago | |
| 14 | Ash 2020 – multiple myeloma goes beyond BCMA | Vantage | 1 year ago | |
| 15 | R/R Multiple Myeloma Rationale for Decreased Response | AJMC.com Managed Markets Network | 1 year ago | |
| 16 | Colin Powell's COVID-19 Death Followed Cancer Diagnosis, Treatment | FactCheck.org | 7 months ago | |
| 17 | ASH 2020: GPRC5D Is a New Target of Interest for Multiple Myeloma | DocWire News | 1 year ago | |
| 18 | Talquetamab Shows Strong Safety and Efficacy Profile When Treating Patients with Heavily Pretreated Myeloma | Cancer Network | 1 year ago | |
| 19 | Case Review: Standard-Risk Multiple Myeloma | Targeted Oncology | 3 years ago | |
| 20 | Novel Triplets Shed New Light on Sequencing in Relapsed/Refractory Myeloma | OncLive | 1 year ago | |
| 21 | Treating Biochemical Relapses in Multiple Myeloma | AJMC.com Managed Markets Network | 1 year ago | |
| 22 | The Future of R/R Multiple Myeloma Management | AJMC.com Managed Markets Network | 1 year ago | |
| 23 | Janssen Presents First Data from the Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma | PR Newswire | 1 year ago | |
| 24 | Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio | PR Newswire | 2 years ago | |
| 25 | Impact of the Phase 3 APOLLO Trial Recent Findings | AJMC.com Managed Markets Network | 1 year ago | |
| 26 | Subcutaneous Daratumumab Appears Primed to Transform Myeloma Care | OncLive | 2 years ago | |
| 27 | Approved Combinations and Novel Agents Expand Therapy Options Across Multiple Myeloma Settings | Targeted Oncology | 3 years ago |